Pramlintide
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypoglycemia
Conditions
Hypoglycemia, Evidence of Previous Gastric Surgery
Trial Timeline
Feb 2, 2010 → Feb 8, 2022
NCT ID
NCT01841359About Pramlintide
Pramlintide is a approved stage product being developed by Bristol Myers Squibb for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01841359. Target conditions include Hypoglycemia, Evidence of Previous Gastric Surgery.
What happened to similar drugs?
1 of 13 similar drugs in Hypoglycemia were approved
Approved (1) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01841359 | Approved | Completed |
Competing Products
20 competing products in Hypoglycemia